Market Access Consulting Deep Dive: Pricing, GTN, IRA Modeling, and How Top Firms Differ in 2026

TL;DR

Market access consulting is a $1B+ services market inside the broader $15B+ pharma commercial consulting space, and the IRA plus Part D redesign have roughly tripled demand for GTN modeling, MFP impact analysis, and payer negotiation preparation since 2023. The field has stratified into five tiers: pharma-only access specialists like Trinity Life Sciences, Avalere, and Precision AQ; broad strategy firms like ZS, Bain, and L.E.K. that bundle access into full launch readiness; data-plus-consulting hybrids led by IQVIA, Lumanity, and IntegriChain; payer and actuarial firms like Milliman and Wakely; and HEOR or pricing boutiques. The top firms differentiate on three axes: proprietary data assets, regulatory track record (especially IRA and 340B), and launch readiness methodology. Pricing varies by an order of magnitude across tiers, and the conflict-of-interest profile varies even more. This is the buyer’s view of who does what, at what price, and when to skip the consultant entirely.

---

Market access consulting scope

The consulting scope spans every commercial decision between clinical proof-of-concept and steady-state contracting. In 2026, most mid-to-large pharma launch teams now run five to eight of the following workstreams through external firms simultaneously.

Pricing strategy sits at the center. The work splits into launch pricing (list price, net price target, payer-channel mix), post-LOE defense (authorized generics, patent cliff bridging, price laddering on remaining indications), and biosimilar defense (contracting depth, interchangeability posture, reference product positioning). Pricing strategy engagements now routinely incorporate IRA selection risk from the first brief.

GTN waterfall modeling is the tactical layer underneath pricing. The waterfall includes commercial rebates, Medicaid best-price obligations, 340B ceilings, Part D catastrophic coverage exposure under the redesign, and copay program cost. Industry GTN medians run 48% to 55% for specialty products and 55% to 70% for high-rebate primary care. The post-redesign rebuild has been the single largest GTN modeling workstream since 2024.

IRA MFP modeling is now a standing workstream, not a one-off project. Firms build selection-risk models covering the Medicare Part D and Part B spend thresholds (products with high Medicare exposure and no generic competition for 7+ years small molecule, 11+ biologic), forecast MFP discount depth scenarios (the 25% to 60% statutory range), and map gross-to-net rebuild paths. Preparing for the CMS negotiation process is a dedicated sub-workstream with scenario planning, evidence packages, and internal alignment work.

Payer contracting strategy covers the actual negotiations: commercial PBM formulary placement, Medicare Part D plan strategy, regional and state Medicaid rebate design, and value-based contract architecture. For specialty launches, this also includes specialty pharmacy network decisions and distribution economics.

Formulary access plans operationalize the strategy: national PBM access targets, regional payer sequencing, IDN carve-outs, Medicaid state-by-state prioritization.

HEOR, AMCP dossier, and value dossier work anchors the clinical-to-commercial handoff. The AMCP Format for Formulary Submissions remains the US reference; globally the EU Joint Clinical Assessment (effective January 2025) has added substantial workload. Most launch teams now build one integrated global value dossier that feeds US, EU, and APAC submissions.

Value-based arrangements and outcomes-based contracts are a specialized sub-practice. Actual execution remains a fraction of announcements, but consulting demand for VBC design, outcomes measurement methodology, and accounting treatment has grown steadily.

Biosimilar and LOE strategy is its own discipline with both offense (biosimilar launch playbooks, interchangeability strategy, substitution pathways) and defense (originator life-cycle, authorized generics, patent extension plays).

---

The firm tiers

There is no single “market access consulting market.” There are five overlapping tiers, and they compete for different slices of the budget.

Tier 1 specialists: pharma-only, deep access DNA

These firms are 100% life sciences-focused with access as their core identity.

• Trinity Life Sciences — 1,600+ professionals. SPARC (Strategy, Pricing, Access, Reimbursement, Contracting) is the flagship US commercialization offering. TGaS Advisors division runs structured benchmarking against top-50 pharma access organizations. Kohlberg-owned with a Bain & Company minority strategic stake.
• Precision AQ — Market access arm of Precision Medicine Group (Blackstone, Berkshire, TPG Growth, Oak HC/FT). 1,200+ dedicated market access and HEOR experts. Access Experience Team (AET) carries 25+ former payer decision-makers as in-house advisors.
• Avalere Health — Regulatory, policy, and market access pedigree rooted in its Washington DC origins. Now part of Fishawack Health (Abry Partners). Strongest CMS, Medicare, Medicaid, and 340B policy track record in the specialist tier.
• Xcenda — Market access arm of Cencora (NYSE: COR, formerly AmerisourceBergen). Access consulting tightly integrated with Cencora’s distribution, 3PL, and specialty pharmacy operations. Conflict profile is specific (see conflict section below).
• Simon-Kucher — Pricing-first consultancy with a deep pharma pricing practice. Often paired with a larger firm on launch pricing, less common on full launch readiness.
• Charles River Associates — Economic consulting firm (NYSE: CRAI) with a life sciences practice known for pricing strategy, HEOR, and regulatory economics. Strong in payer negotiation support.

Tier 1 broad consulting

These firms are not access-first, but their access practices are large and top-of-mind in CEO-level RFPs.

• ZS Associates — 13,000+ professionals, privately held. Life sciences is the majority of revenue. Launch readiness, forecasting, patient services strategy, and field-force design are strengths; access is embedded in every launch engagement.
• L.E.K. Consulting — Boutique strategy with an outsized life sciences practice. Strong in due diligence, commercial strategy, and product valuation. Market access is a complementary workstream inside launch strategy engagements.
• Bain Life Sciences — Bain & Company’s dedicated life sciences practice, with a strong foothold in pharma CEO and board-level work. The minority strategic stake in Trinity Life Sciences (2022) gives Bain a quasi-partnered market access capability.
• McKinsey Pharma — McKinsey’s pharma practice runs deep launch excellence benchmarks and transformation programs. Not access-native; usually paired with a specialist.
• BCG Life Sciences — Similar profile to McKinsey; strategic, top-down, typically brought in for enterprise-level questions (portfolio choices, M&A, operating model) more than tactical access plans.

Data plus consulting hybrids

These firms sell data subscriptions and strategy consulting from the same house.

• IQVIA Consulting — MIDAS (90+ country pricing), NSP/NPA (roughly 93% of US Rx), LAAD, OneKey. Consulting practice leverages the data moat, especially on international reference pricing and launch analytics.
• Lumanity — 1,200+ professionals. HEOR-anchored (BresMed heritage), with strong HTA submission track record including first-ever NICE submissions in CAR-T, immuno-oncology, and AMR. Arsenal Capital-backed.
• IntegriChain — GTN and government pricing platform (ICyte) paired with advisory services. Default infrastructure partner for rebate operations, Medicaid state price reporting, and Part D redesign GTN rebuild.
• Komodo Health Consulting — Healthcare Map provides a large closed-claims dataset layered with consulting. Strongest in epidemiology, patient journey, and HCP targeting work that feeds access strategy.
• ClearPoint Health Consulting — Claims and clinical data plus advisory. A smaller challenger in the hybrid tier.

Payer and actuarial firms

These firms bring actuarial rigor to access modeling and often serve both pharma and payer sides of the market.

• Milliman — One of the largest actuarial firms globally. Milliman’s pharma work leans heavily on PBM and payer-side modeling, plus IRA impact actuarial analysis. Strong in Part D redesign plan-level modeling.
• Wakely Consulting Group — Actuarial and policy firm, deeply engaged on ACA, Medicaid managed care, and Part D. Known for regulatory compliance and rate filing work; growing pharma pricing footprint.
• Oliver Wyman — Strategy consulting with strong health and insurance practice. Cross-stakeholder access work spanning payers, providers, and pharma.

Boutiques

Smaller, specialist firms with tight practice areas.

• Numerof & Associates — Value-based care and outcomes contracting specialist.
• Health Advances — Commercial strategy boutique with strong life sciences due diligence practice.
• Marwood Group — DC-based advisory focused on healthcare policy, regulatory strategy, and government affairs.
• Putnam Associates — Commercial strategy boutique with pricing and access capabilities, common choice for small-to-mid biotech.

---

Head-to-head comparison

The ten-dimension view. Ratings are directional, reflecting where each firm is strongest against the specific access workstream. A low rating does not mean the firm is weak overall.

Dimension	Trinity	Avalere	Precision AQ	ZS	Bain	McKinsey	L.E.K.	Simon-Kucher	CRA	IQVIA	Lumanity	IntegriChain	Milliman
IRA MFP modeling depth	5	5	5	3	3	3	3	3	4	4	4	4	4
GTN tools owned / partnered	Partnered	Partnered	Partnered	None	None	None	None	None	None	Partnered	Partnered	Owned (ICyte)	None
Payer relationships	Strong	Strong (policy)	AET (25+ ex-payers)	Moderate	Moderate	Moderate	Light	Light	Moderate	Via data	Moderate	Via data	Strong (actuarial)
Launch readiness methodology	5	3	5	5	5	5	5	3	3	4	5	3	2
HEOR / value dossier	3	4	5	4	3	3	3	2	4	4	5	2	3
340B strategy	4	5	4	2	2	3	2	2	3	3	2	3	3
Part D redesign GTN rebuild	5	5	4	3	3	3	3	3	3	4	3	5	5
Global access / HTA	3	3	4	4	4	4	3	3	4	5	5	2	3
Typical engagement size	$500K-2M	$300K-1.5M	$500K-2M	$1-5M	$1-5M	$1-5M	$750K-3M	$250K-1M	$200K-1M	$500K-2M	$500K-2M	$300K-1M	$100K-400K
Differentiator	US pricing + TGaS benchmarking	CMS/policy DNA	AET ex-payer panel	Full launch + forecasting	CEO/board access	Transformation + launch excellence	Due diligence + strategy	Pricing purist	Economic expert work	Data moat	HEOR + HTA	GTN infrastructure	Actuarial rigor

Engagement ranges are industry benchmark, reflect fully-loaded project fees, and vary widely with scope.

---

Pricing tiers

The five tiers have distinct price architectures. All figures are industry benchmark ranges for 2026; actual fees vary with scope, seniority mix, and retainer structure.

Tier 1 specialists (Trinity, Avalere, Precision AQ, Xcenda, Simon-Kucher, CRA)

• Senior consultant / partner rates (industry benchmark): $300 to $500 per hour.
• Typical engagement size: $500K to $2M per launch. Pricing strategy and payer research modules often run $300K to $600K as stand-alones. Integrated launch access engagements (covering pricing, payer strategy, HEOR, and GTN modeling) land at the high end.
• Retainer pattern: Many specialists sell multi-phase retainers layered across the Phase II to launch window, often $150K to $350K per quarter for an active brand.
• Named reference points: Trinity’s SPARC end-to-end offering is typically in the $750K to $2M range per launch. TGaS Advisors benchmarking subscriptions (separate product) run roughly $150K to $400K annually depending on scope.

Tier 1 broad (ZS, Bain, McKinsey, BCG, L.E.K.)

• Senior partner rates (industry benchmark): $450 to $700 per hour. McKinsey and Bain tend to be at the top of the range; L.E.K. and ZS at the mid.
• Typical engagement size: $1M to $5M+ for integrated launch readiness. Full launch sprints at McKinsey or Bain often run $3M to $6M over 16 to 24 weeks.
• Retainer pattern: Less common; most work is project-based with clear milestones. Post-launch follow-on engagements are frequent but rarely labeled retainers.
• Characteristic spend profile: One large commercial excellence engagement (roughly $3M) plus 2 to 3 smaller specialist projects ($500K each) over 18 months is a common top-25 pharma pattern.

Data plus consulting hybrids (IQVIA, Lumanity, IntegriChain, Komodo, ClearPoint)

• Senior rates (industry benchmark): $300 to $500 per hour on consulting; data is licensed separately.
• Subscription floor: $300K to $500K annually for core data access (IQVIA MIDAS modules, Komodo Healthcare Map tier, Lumanity HTA databases). IntegriChain’s ICyte GTN platform is typically a seven-figure annual fee for top-50 pharma, lower for mid-size biotech.
• Project layer: $250K to $1M+ per project on top of subscriptions. IQVIA engagements above $2M are common when consulting is bundled with substantial data licensing and analytics hosting.
• Distinctive feature: The subscription floor creates a steady revenue base and rationalizes aggressive consulting pricing on tactical work.

Payer and actuarial (Milliman, Wakely, Oliver Wyman)

• Senior rates (industry benchmark): $200 to $400 per hour. Milliman’s pharma-facing rate card is at the upper end of this tier.
• Typical engagement size: $100K to $400K per project. IRA Part D redesign actuarial analysis is a common $250K to $400K engagement; plan-level rate filing support is lower.
• Distinctive feature: Credentialed actuaries, stronger payer-side pattern of work, and regulatory filing work that pure strategy firms do not touch.

Boutiques (Numerof, Health Advances, Marwood, Putnam)

• Senior rates (industry benchmark): $200 to $350 per hour.
• Typical engagement size: $50K to $300K per engagement. Small biotech pricing strategy work is often $75K to $150K; diligence support for PE or corporate development typically $100K to $250K.
• Distinctive feature: Direct partner staffing, quick turnarounds, and lower minimum scope than any Tier 1 firm will accept.

---

IRA-era specialization

The IRA and Part D redesign have rewritten the market access brief. Five specializations now dominate new-business pitches.

MFP impact modeling

Trinity, Avalere, and Precision AQ lead the selection-risk and Maximum Fair Price scenario-modeling work. The standard deliverable is a portfolio heat map (product by Medicare exposure, patent life, and competitive landscape) plus a scenario model of MFP discount depth ranging from the 25% minimum statutory ceiling to 60% for long-life single-source products. Milliman is the go-to for the actuarial version of the same analysis, especially for plan-side impact.

Small-molecule vs biologic IRA clock

The 7-year vs 11-year window for negotiation eligibility is the single most consequential portfolio decision on the table. Firms with both pricing and R&D strategy DNA (Bain, McKinsey, ZS, Trinity) advise on portfolio reshaping in light of this gap. The clock has already affected several announced deprioritizations of small-molecule programs in favor of biologic alternatives, and the consulting demand for this specific question is steady.

Part D redesign GTN rebuild

The 2025 Part D redesign (new out-of-pocket cap, restructured manufacturer liability in the catastrophic phase) has forced a full GTN rebuild for every brand with meaningful Part D mix. IntegriChain and Model N’s partner ecosystems are the dominant GTN infrastructure. Trinity, Avalere, and Milliman lead the strategy and scenario work on top of that infrastructure.

340B strategy

Avalere and Precision AQ have the deepest 340B track record. Trinity is a close third. The work is a mix of contract pharmacy audits, integrity programs, legal strategy (typically co-led with firms like Duane Morris or Frier Levitt), and pricing scenario modeling. 340B ceiling price strategy interacts directly with IRA MFP modeling because the MFP becomes the effective ceiling for the 340B calculation.

Specialty launch under the redesign

For specialty launches with high Medicare exposure, the interaction of MFP eligibility, Part D redesign phases, and patient out-of-pocket dynamics has produced a new launch methodology. Trinity, Precision AQ, and ZS now market distinct “redesign-ready launch” frameworks. The substance varies; the pattern is clear.

---

How to shortlist

Shortlists should match the dominant question, not the brand of the firm. These pairings are the most-common short lists in 2026 biotech and pharma access RFPs.

• For IRA modeling: Trinity, Avalere, Precision AQ.
• For launch readiness: Trinity, ZS, L.E.K.
• For payer negotiation: Trinity, Avalere, Charles River Associates.
• For post-LOE defense: Bain, L.E.K., Simon-Kucher.
• For HEOR / value dossier: Lumanity, Precision AQ, ZS.
• For GTN rebuild under Part D redesign: IntegriChain plus Trinity or Avalere on strategy.
• For global HTA strategy: Lumanity, IQVIA, Precision AQ.
• For 340B strategy: Avalere, Precision AQ, Trinity.
• For small biotech pricing with a tight budget: Putnam, Health Advances, Simon-Kucher.
• For CEO or board-level portfolio work with an access overlay: Bain, McKinsey, BCG, paired with a specialist below.

The strongest launches typically pair one specialist with one broad firm: for example, Trinity on SPARC plus ZS on launch readiness, or Precision AQ on payer strategy plus Bain on portfolio optimization. The dual engagement model has become the norm for top-10 launches.

---

Conflict-of-interest check

Vendor conflicts are the single most under-discussed part of market access consulting. Every firm has a conflict profile. The question is whether it is disclosed and whether it shapes the recommendation.

Vendors who also sell data — IQVIA, Lumanity, Komodo Health, IntegriChain — have a structural incentive to recommend their own dataset as the correct tool for the answer. The resulting advice is not wrong; it is just not independent. A Komodo consulting engagement will use the Healthcare Map; an IQVIA engagement will default to MIDAS and NSP. For a buyer who has already licensed those datasets, this is an advantage. For a buyer still making the data decision, it is a bias.

Vendors who sell downstream services — Xcenda (Cencora), IntegriChain, EVERSANA — have a structural incentive to recommend their own distribution, 3PL, GTN, or hub platform. Xcenda’s 3PL / specialty pharmacy / distribution integration means its recommendations on channel strategy should be pressure-tested against an independent voice. IntegriChain’s ICyte platform will often be the recommended GTN tool at the end of an IntegriChain GTN strategy engagement.

Vendors tied to PE or strategic investors — Trinity (Kohlberg, Bain minority), Precision AQ (Blackstone, Berkshire, TPG, Oak HC/FT), Lumanity (Arsenal) — have softer conflicts. The PE timeline affects team continuity and pricing discipline but usually not the substance of the recommendation.

The independent-first framework. For the most consequential decisions (a $500M net-price target, a Medicare Part D redesign rebuild, an IRA negotiation posture), commission at least one parallel workstream from a firm with no financial interest in the downstream services or data stack. That is typically a Tier 1 specialist without a data or hub product, a pure pricing consultancy like Simon-Kucher or CRA, or a boutique.

The full framework here would treat these structural tensions systematically across vendor categories.

---

When you don’t need a consultant

The value of market access consulting is not universal. Three situations justify skipping it.

Simple primary-care launches with known access dynamics. A non-specialty product entering a crowded therapeutic area (second-line statin, fifth DPP-4, a new SSRI generic) has well-understood payer mechanics, established rebate expectations, and internal teams that have shipped comparable products. The marginal value of a $500K pricing and access engagement is small relative to a well-staffed internal team.

Post-LOE cases where the internal team has seen the playbook. A large pharma approaching its third or fourth LOE defense on a mature franchise typically has a documented playbook, an in-house authorized generic partner, and contracting patterns that do not require external strategy. External support may still be useful for specific workstreams (legal, 340B audit, regulatory) but not for the full defense program.

Biosimilar launches at an inflection point where payer precedent is set. Second-wave biosimilars in categories with multiple precedents (TNF-alpha, oncology supportive care) enter a market with stable payer behavior. Formulary architecture, rebate depth, and interchangeability posture are known. External strategy is typically lower value than internal operational execution.

The inverse is also true. First-in-class launches, rare disease with unknown payer response, high-Medicare-exposure specialty, and any IRA-eligible asset all justify significant consulting spend because the cost of a 2% GTN miss or a six-month access delay dwarfs the consulting fee.

---

Cross-reference

• IRA MFP Impact on Pharma Services Vendors — how MFP reshapes the services market.
• Part D Redesign and Copay Accumulator Impact — the mechanics underneath GTN rebuild.
• Hub Services Market Analysis — downstream market context.
• Pharma Services Market Sizing — full services market map.

---

Verdict

The honest framing of 2026 market access consulting is that the answer is almost never one firm. The top launches pair a Tier 1 specialist (Trinity, Avalere, or Precision AQ) for access strategy with a broad firm (ZS, Bain, or L.E.K.) for launch readiness, overlay a data-plus-consulting hybrid (IQVIA or Lumanity) for specific data work, and reserve an actuarial or boutique for independent pressure-testing on the most consequential numbers. The firms are not interchangeable, the pricing is not comparable, and the conflict profiles matter. Buyers who pick based on the brand name rather than the specific question almost always overpay and under-specify.